Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oramed Pharmaceuticals Inc. Director's Dealing 2025

Jan 6, 2025

6965_dirs_2025-01-06_f72dd45a-7ecd-4eda-bd75-f91edf24b578.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2025-01-02

Reporting Person: Hexter Joshua (COO & CBO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-01-02 Common Stock A 194500 Acquired 706333 Direct

Footnotes

F1: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 16,208 over a three year period starting January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.